Author

Valeriya V. Saevets

Observed names: V V Saevets, V. Saevets, V. V. Saevec, V. V. Saevets, V. V. Saevets, V.V. Saevec, V.V. Saevets, V. V. Saevets, Valeria V. Saevets, Valeriya Saevets, Valeriya Vladimirovna Saevets, В. В. Саевец, Валерия Саевец

Institutions: Chelyabinsk State Medical Academy, Chelyabinsk Regional Clinical Oncology Center

Observed institutions: Chelyabinsk State Medical Academy, Ural State Medical University, Ministry of Health of the Russian Federation, Chelyabinsk Regional Clinical Oncology Center

ORCID: 0000-0003-2572-2408

Observed ORCID: 0000-0003-2572-2408

OpenAlex ID: A5084456265

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

2024 · Domenica Lorusso, Yang Xiang, et al. · The Lancet · 456

2024 · Domenica Lorusso, Yang Xiang, et al. · The Lancet · 248

Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study

2026 · Nicoletta Colombo, Emese Zsiros, et al. · The Lancet · 74

LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

2023 · D. Lorusso, Y. Xiang, et al. · Annals of Oncology · 41

PDF

Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer

2025 · Leslie Randall, Yang Xiang, et al. · Gynecologic Oncology · 12

709O Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

2024 · D. Lorusso, Y. Xiang, et al. · Annals of Oncology · 7

PDF

Current approaches to the treatment of advanced ovarian cancer using PET / CT-guided hyperthermic chemoperfusion. A clinical experience

2019 · V. V. Saevets, A. V. Taratonov, et al. · Malignant tumours · 5

PDF

Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

2024 · Linda Duska, Yang Xiang, et al. · Gynecologic Oncology · 3

Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical Trial

2024 · Domenica Lorusso, Yang Xiang, et al. · Obstetrical & Gynecological Survey · 3

161 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: the randomized, double-blind, phase 3 ENGOT-Cx11/GOG-3047/KEYNOTE-A18 study

2024 · Domenica Lorusso, Yang Xiang, et al. · International Journal of Gynecological Cancer · 3

Surgical Treatment of Patients With Cancer of the Vulva

2018 · Aleksandr Zharov, Galina Kravchenko, et al. · Voprosy Onkologii · 3

PDF

Features of multimodal treatment of locally-advanced cervix cancer regarding to the tumor histology

2015 · V. V. Saevec, ANDREJ VAZHENIN, et al. · Malignant tumours · 3

PDF

Cost-effectiveness of using granulocyte colony-stimulating factor in the treatment of uterine body leiomyosarcomas. A retrospective analysis

2024 · Valeriya V. Saevets, Nikita K. Kuzmin, et al. · Journal of Modern Oncology · 2

PDF

Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer

2024 · Leslie Randall, Vladyslav Sukhin, et al. · Gynecologic Oncology · 2

Clinical and economic benefits of parenteral iron carboxymaltosate in patients with gynecological cancers: A retrospective observational study

2023 · Valeriya V. Saevets, Anna Yu. Shamanova · Journal of Modern Oncology · 2

PDF

Редкие злокачественные опухоли вульвы: клиника, диагностика, подходы к лечению

2023 · В. В. Саевец, Д. М. Ростовцев, et al. · Malignant tumours · 2

PDF

Approaches to therapy for ovarian cancer yesterday, today, tomorrow

2023 · V.V. Saevets, A.Yu. Shamanova, et al. · P A Herzen Journal of Oncology · 2

Role of hyperthermic intraperitoneal chemotherapy in combination with an intraperitoneal port system in the treatment of patients with advanced ovarian cancer

2021 · V. V. Saevets, A. V. Privalov, et al. · Tumors of female reproductive system · 2

PDF

Lymphadenectomy for oncogynecological pathology: evaluation of lymph cyst formation and detection of metastases depending on the number of lymph nodes removed

2021 · V. V. Saevets, Yu. A. Semenov, et al. · Ural Medical Journal · 2

PDF

Treatment of advanced-stage ovarian cancer including combination of intra-abdominal chemotherapy

2021 · V. V. Saevets, A. V. Privalov, et al. · Ural Medical Journal · 2

Analysis of economic efficiency of iron deficiency anemia therapy in patients with malignant tumors

2021 · V. V. Saevets, А. Р. Alekseeva, et al. · Ural Medical Journal · 2

PDF

Intermediate results of the PERFECTION observational study in a population of patients with metastatic, persistent and recurrent cervical cancer

2025 · Valeria V. Saevets, Nikita K. Kuzmin, et al. · Journal of Modern Oncology · 1

PDF

2025 · Domenica Lorusso, Yang Xiang, et al. · Obstetrical & Gynecological Survey · 1

What we know about the new coronavirus infection in cancer patients

2025 · P. S. Feoktistova, E. A. Azarova, et al. · Malignant tumours · 1

PDF

Undifferentiated pancreatic carcinoma with osteoclast-like giant cells

2023 · A.Yu. Shamanova, D.M. Rostovtsev, et al. · Russian Journal of Archive of Pathology · 1

Works count: 48

Citation count: 885

H-index: 6

I10-index: 5